Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases
Modification of proteins by glycans plays a crucial role in mediating biological functions in both healthy and diseased states. Mass spectrometry (MS) has emerged as the most powerful tool for glycomic and glycoproteomic analyses advancing knowledge of many diseases. Such diseases include those of t...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-07-01
|
| Series: | Frontiers in Chemistry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fchem.2021.707387/full |
| _version_ | 1818652353149009920 |
|---|---|
| author | Dylan Nicholas Tabang Megan Ford Lingjun Li Lingjun Li |
| author_facet | Dylan Nicholas Tabang Megan Ford Lingjun Li Lingjun Li |
| author_sort | Dylan Nicholas Tabang |
| collection | DOAJ |
| description | Modification of proteins by glycans plays a crucial role in mediating biological functions in both healthy and diseased states. Mass spectrometry (MS) has emerged as the most powerful tool for glycomic and glycoproteomic analyses advancing knowledge of many diseases. Such diseases include those of the pancreas which affect millions of people each year. In this review, recent advances in pancreatic disease research facilitated by MS-based glycomic and glycoproteomic studies will be examined with a focus on diabetes and pancreatic cancer. The last decade, and especially the last five years, has witnessed developments in both discovering new glycan or glycoprotein biomarkers and analyzing the links between glycans and disease pathology through MS-based studies. The strength of MS lies in the specificity and sensitivity of liquid chromatography-electrospray ionization MS for measuring a wide range of biomolecules from limited sample amounts from many sample types, greatly enhancing and accelerating the biomarker discovery process. Furthermore, imaging MS of glycans enabled by matrix-assisted laser desorption/ionization has proven useful in complementing histology and immunohistochemistry to monitor pancreatic disease progression. Advances in biological understanding and analytical techniques, as well as challenges and future directions for the field, will be discussed. |
| first_indexed | 2024-12-17T02:20:39Z |
| format | Article |
| id | doaj.art-16a7d3bdb2d944cdbbdac8568ffce392 |
| institution | Directory Open Access Journal |
| issn | 2296-2646 |
| language | English |
| last_indexed | 2024-12-17T02:20:39Z |
| publishDate | 2021-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Chemistry |
| spelling | doaj.art-16a7d3bdb2d944cdbbdac8568ffce3922022-12-21T22:07:17ZengFrontiers Media S.A.Frontiers in Chemistry2296-26462021-07-01910.3389/fchem.2021.707387707387Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic DiseasesDylan Nicholas Tabang0Megan Ford1Lingjun Li2Lingjun Li3Department of Chemistry, University of Wisconsin-Madison, Madison, WI, United StatesDepartment of Chemical and Biological Engineering, University of Wisconsin-Madison, Madison, WI, United StatesDepartment of Chemistry, University of Wisconsin-Madison, Madison, WI, United StatesSchool of Pharmacy, University of Wisconsin-Madison, Madison, WI, United StatesModification of proteins by glycans plays a crucial role in mediating biological functions in both healthy and diseased states. Mass spectrometry (MS) has emerged as the most powerful tool for glycomic and glycoproteomic analyses advancing knowledge of many diseases. Such diseases include those of the pancreas which affect millions of people each year. In this review, recent advances in pancreatic disease research facilitated by MS-based glycomic and glycoproteomic studies will be examined with a focus on diabetes and pancreatic cancer. The last decade, and especially the last five years, has witnessed developments in both discovering new glycan or glycoprotein biomarkers and analyzing the links between glycans and disease pathology through MS-based studies. The strength of MS lies in the specificity and sensitivity of liquid chromatography-electrospray ionization MS for measuring a wide range of biomolecules from limited sample amounts from many sample types, greatly enhancing and accelerating the biomarker discovery process. Furthermore, imaging MS of glycans enabled by matrix-assisted laser desorption/ionization has proven useful in complementing histology and immunohistochemistry to monitor pancreatic disease progression. Advances in biological understanding and analytical techniques, as well as challenges and future directions for the field, will be discussed.https://www.frontiersin.org/articles/10.3389/fchem.2021.707387/fullmass spectrometryglycosylationglycationpancreatic cancerpancreatitisdiabetes |
| spellingShingle | Dylan Nicholas Tabang Megan Ford Lingjun Li Lingjun Li Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases Frontiers in Chemistry mass spectrometry glycosylation glycation pancreatic cancer pancreatitis diabetes |
| title | Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases |
| title_full | Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases |
| title_fullStr | Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases |
| title_full_unstemmed | Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases |
| title_short | Recent Advances in Mass Spectrometry-Based Glycomic and Glycoproteomic Studies of Pancreatic Diseases |
| title_sort | recent advances in mass spectrometry based glycomic and glycoproteomic studies of pancreatic diseases |
| topic | mass spectrometry glycosylation glycation pancreatic cancer pancreatitis diabetes |
| url | https://www.frontiersin.org/articles/10.3389/fchem.2021.707387/full |
| work_keys_str_mv | AT dylannicholastabang recentadvancesinmassspectrometrybasedglycomicandglycoproteomicstudiesofpancreaticdiseases AT meganford recentadvancesinmassspectrometrybasedglycomicandglycoproteomicstudiesofpancreaticdiseases AT lingjunli recentadvancesinmassspectrometrybasedglycomicandglycoproteomicstudiesofpancreaticdiseases AT lingjunli recentadvancesinmassspectrometrybasedglycomicandglycoproteomicstudiesofpancreaticdiseases |